The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. (Q54713883)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

7

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

author name string

A Pardanani

1

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

T L Lasho

2

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

C M Finke

3

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

N Gangat

4

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

A P Wolanskyj

5

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

C A Hanson

6

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

publication date

22 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

24

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

1

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

110-114

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

https://scigraph.springernature.com/pub.10.1038/leu.2009.226

0 references

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Mutation in TET2 in myeloid cancers

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

21 January 2018

Mutations of ASXL1 gene in myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.226

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.226

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 June 2018

http://europepmc.org/abstract/MED/19847198

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54713883&oldid=1456800667"